loader2
Login Open ICICI 3-in-1 Account
Open ICICI 3-in-1 Account

Apollo Hospitals Enterprise Results: Latest Quarterly Results & Analysis

Open Free Trading Account Online with ICICIDIRECT
+91
Apollo Hospitals Enterprise Ltd. 13 Aug 2025 11:41 AM
Result PDF

Q1FY26 Quarterly Result Announced for Apollo Hospitals Enterprise Ltd.

Healthcare Facilities company Apollo Hospitals Enterprise announced Q1FY26 results

  • Revenues at Rs 5,842 crore vs Rs 5,086 crore in Q1FY25; growth of 15% YoY.
  • EBITDA at Rs 852 crore vs Rs 675 crore in Q1FY25. This is after Apollo 24/7 cost of Rs 121 crore in the quarter (incl. Rs 24 crore non-cash ESOP charge) vs Rs 150 crore in Q1FY25.
  • Reported PAT at Rs 433 crore vs Rs 305 crore in Q1FY25
  • Diluted EPS of Rs 30.10 per share in Q1FY26 (not annualised).

Prathap C Reddy, Chairman, Apollo Hospitals Enterprise Ltd. said: ''I am proud to see the resilient comeback in the first quarter of FY26, building on the strong foundation of Q4FY25. I am glad to inform you that Q1FY26 has delivered another robust set of results, with revenue growth in the double digits at 15% YoY and continued improvement in margins. Our performance demonstrates the power and resilience of our integrated model of healthcare delivery, with all three engines - our core divisions, Healthcare Services, Retail Healthcare & Diagnostics, and Digital & Pharma Distribution- contributing to our performance.

Patient numbers across our network increased year-on-year, reflecting both the deeper penetration of our Centres of Excellence and the growing confidence of communities in our integrated care model. The quarter saw us announce our ambitious growth strategy to add over 4,300 beds in the next five years with an investment of over ~7,600 crore. The first phase of 2,000 beds is already in progress. We have added an existing 200-bed hospital in Bengaluru and will also be establishing a 500-bed greenfield hospital in the suburbs of the city to bring the total bed strength in Bengaluru to 1,500 beds. In Hyderabad, we are adding 160 beds at our existing Jubilee Hills and Secunderabad facilities, and with the upcoming facility in Gachibowli, our bed strength in the city will increase to 1,400 beds.

On the digital front, Apollo 24/7 achieved a quarterly GMV of over Rs 682 crore, sustaining the platform's momentum and signalling the continuing strong demand for teleconsultations, lab and pharmacy deliveries. This performance builds on the platform's FY25 GMV of Rs 3,007 crore, demonstrating our success in creating a seamless care continuum from home to hospital.

The demerger of our digital health and pharmacy business, approved in the last quarter, is now in the implementation phase. This strategic move will enable focused capital allocation and sharper growth plans with dedicated management teams for both hospital operations and the omnichannel healthcare ecosystem, a structure designed to maximise synergies while preserving the Apollo ethos of quality and trust.

Preventive healthcare remains at the heart of our mission. Through the AI-based Apollo ProHealth platform, we have crossed 25Million health assessments this quarter alone, guiding individuals on personalised wellness journeys and strengthening early-detection pathways.

Patient access continues to guide our investments. We expanded our 'Care-Within-Reach' financing programs to additional tier 2 and tier 3 markets, ensuring that advanced treatments remain accessible to a broad segment of the population. Our efforts on sustainability saw us launch 'Green Health' initiatives in Mumbai and Hyderabad, achieving a 20% reduction in energy consumption per patient day and using eco-friendly materials across new construction projects.

Looking ahead, we anticipate continued double-digit revenue growth for FY26, underpinned by new hospital openings in Patna and Jaipur slated for QJ, further digital innovation, and deepening partnerships with state governments to bolster community-based health initiatives. I remain confident that Apollo will set new benchmarks in clinical excellence, patient experience, and sustainable growth-true to our founding mission of enabling healthier, happier lives for all."

Result PDF

Result PDF

Healthcare Facilities company Apollo Hospitals Enterprise announced Q3FY25 results

  • Revenues at Rs 55,269 million vs Rs 48,506 million in Q3FY24; growth of 14% YoY
  • EBITDA at Rs 7,615 million vs Rs 6,137 million in Q3 FY24. This is after Apollo 24/7 cost of Rs 1,405 million in the quarter (including Rs 268 million non-cash ESOP charge) vs Rs 1,557 million in Q3FY24.
  • Reported PAT at Rs 3,723 million vs Rs 2,453 million in Q3FY24.
  • Diluted EPS of Rs 25.89 per share in Q3FY25 (not annualized).

Prathap C Reddy, Chairman, Apollo Hospitals Enterprise, said: At Apollo Hospitals, we have always measured success by the lives we touch and the impact we create for a healthier nation. With Q3FY25 revenues rising by 14% to Rs 5,527 crore and EBITDA by 24% to Rs 762 crore, our performance is a testament to our commitment of a healthier India by bringing cutting-edge technologies to everyone who needs it. We are on track to add 3,512 beds across 11 locations over 3 to 4 years beginning FY26. The results reflect our growth story that underlines our purpose of healing India and touching more than a billion lives. From Mumbai to Varanasi and Chennai to Gurugram, we are committed to ensuring that quality healthcare is not a privilege but a fundamental right for all.

Our strategic partnership with Microsoft is accelerating our Al-driven healthcare transformation, including innovation in disease progression, and genomics. By collaborating with the University of Leicester, we are equipping the next generation of healthcare professionals with unmatched skills. Taking our impact global, Apollo Hospitals Enterprise Limited (AHEL) signed a landmark Memorandum of Understanding (MoU) with Mayapada Healthcare Group, Indonesia to transform the region's healthcare landscape by enhancing medical capabilities, clinical programs, and operational excellence in oncology, cardiology, neurology, and transplant surgery.

At Apollo Hospitals, we recognise the rising burden of cancer and launched Unify to Notity campaign towards classifying cancer as a notifiable disease. Our pursuit of enhancing our clinical excellence continues with landmark surgeries and treatments at our hospitals across India. Apollo Hospitals, Chennai achieved a remarkable benchmark in cardiac care by completing 500 robotic cardiac surgeries. Apollo Hospitals, Bangalore performed a robotic knee replacement surgery on a 17-year-old boy, the youngest reported case in the world, who was struggling with severe A vascular Necrosis.

As we look ahead, we are confident about our plans to creat a sustainable impact and value to 'Heal in India' and 'Heal by India' with world-class healthcare and cutting-edge innovation not just for India but for the world."

Result PDF

Healthcare Facilities company Apollo Hospitals Enterprise announced H1FY25 & Q2FY25 results

Q2FY25 Financial Highlights:

  • Q2FY25 Revenues grew to Rs 5,589 crore; 15% YoY growth
    • Healthcare Services (HCS) Revenue at Rs 2,903 Crore; 14% YoY growth
    • AHLL: Revenues at Rs 404 crore; 14% YoY growth
    • Apollo HealthCo: Pharmacy Distribution & Digital Health Revenues at Rs 2,282 crore; 17% YoY growth
    • GMV of Apollo 24/7 at Rs 757 crore.
  • Q2FY25 Consolidated EBITDA stood at Rs 816 crore; 30% YoY growth
    • Healthcare Services (HCS) EBITDA at Rs 722 crore; YoY growth of 14%
    • AHLL EBITDA at Rs 41 crore; YoY growth of 30%
    • Apollo HealthCo: Pharmacy distribution & Digital health EBITDA at Rs 52 crore
  • Q2FY25 Consolidated PAT Rs 379 crore, compared to Rs 233 crore in Q2 FY24; 63% YoY growth
    • Healthcare Services (HCS) PAT at Rs 364 Crore; YoY growth of 16%.

H1FY25 Financial Highlights:

  • H1FY25 Revenues grew to Rs 10,675 crore; 15% YoY growth
    • Healthcare Services (HCS) Revenue at Rs 5,541 crore; 14% YoY growth
    • AHLL: Revenues at Rs 770 crore; 14% YoY growth
    •  Apollo HealthCo: Pharmacy Distribution & Digital Health Revenues at Rs 4,364 crore;16% YoY growth
    • GMV of Apollo 24/7 at Rs 1,452 crore
  • H1FY25 Consolidated EBITDA stood at Rs 1,491 crore; 31% YoY growth
    • Healthcare Services (HCS) EBITDA at Rs 1,344 crore; YoY growth of 14%
    • AHLL EBITDA at Rs 72 crore; YoY growth of 31%
    • Apollo HealthCo: Pharmacy distribution & Digital health EBITDA at Rs 75 crore
  • H1 FY25 Consolidated PAT Rs 684 crore, compared to Rs 400 crore in H1 FY24; 71% YoY growth
    • Healthcare Services (HCS) PAT at Rs 693 Crore; YoY growth of 20%

Prathap C Reddy, Founder & Chairman, Apollo Hospitals Group said: "Apollo Hospitals, we are dedicated to continually evolving to meet the changing healthcare needs of our nation. Through strategic initiatives like our investment in Apollo Health and Lifestyle and the launch of new multi-specialty hospitals, we reaffirm our commitment. to expand access to high-quality healthcare across India, particularly in regions where critical care access is essential.

One of our proudest achievements is our recent partnership with the Government of Tripura to provide free heart surgeries for children, underscoring our belief that healthcare should reach those who need it most, especially in underserved communities. Beyond expanding access, we are advancing medical technology with innovative treatments like water vapor thermotherapy for prostate care and robotic radiosurgery systems for cancer. These state-of-the-art solutions make procedures less invasive and reduce recovery time, resulting in better patient outcomes.

We're also investing in the future of healthcare with the launch of our new research academy, which is focused on driving groundbreaking medical discoveries that will shape the next generation of treatments. Our priorities remain clear-enhancing patient care, prioritizing safety, and advancing medical science.

The first half of FY25 has been an exciting time for us, marked by these major milestones aimed at extending the reach and impact of our healthcare services. Moving forward, our mission is simple: to push the boundaries of healthcare and ensure that everyone, regardless of where they live, has access to the best medical services. This is our promise, and we are committed to making it a reality."

Result PDF

Healthcare Facilities company Apollo Hospitals Enterprise announced Q3FY24 & 9MFY24 results:

Consolidated Q3FY24:

  • Revenues at Rs 48,506 million vs Rs 42,636 million in Q3FY23; growth of 14% YoY
  • EBITDA at Rs 6,137 million vs Rs 5,053 million in Q3FY23. This is after Apollo 247 cost of Rs 1,557 million in the quarter (including Rs 141 million non-cash ESOP charge) vs Rs 2,024 million in Q3 FY23.
  • Reported PAT at Rs 2,453 million vs Rs 1,535 million in Q3FY23
  • Diluted EPS of Rs 17.06 per share in Q3FY24 (not annualized)

Consolidated 9MFY24:

  • Revenue at Rs 141,153 million vs Rs123,103 million in 9MFY24; growth of 15% YoY
  • EBITDA at Rs 17,502 million vs Rs 15,615 million in 9MFY23. This is after Apollo 247 cost of Rs 5,569 million for 9M(including Rs 785 million non-cash ESOP charge) vs Rs 5,181 million in 9MFY23.
  • PAT stood at Rs 6,448 million vs Rs 5,315 million in 9MFY23
  • Reported PAT stood at Rs 6,448 million vs Rs 6,746 million in 9MFY23
  • Diluted EPS of Rs 44.84 per share in 9MFY24

Health Care service Q3FY24 Performance:

  • Revenue at Rs 24,635 million vs Rs 21,944 million in Q3 FY23; growth of 12% YoY
  • EBITDA grew by 8% at Rs 5,860 million vs Rs 5,428 million in Q3FY23; Margins at 23.8% in Q3FY24
  • PAT stood at Rs 2,872 million vs Rs 2,609 million in Q3FY23, 10% growth

Health Care service 9MFY24 Performance:

  • Revenue at Rs 73,044 million vs Rs 64,823 million in 9MFY23; growth of 13% YoY
  • EBITDA grew by 10% at Rs 17,627 million vs Rs 15,984 million in 9MFY23; Margins at 24.1% in 9MFY24
  • PAT stood at Rs 8,648 million vs Rs 9,043 million in 9MFY23

Dr. Prathap C Reddy, Chairman, Apollo Hospitals Group said, "In the pursuit of a healthier nation, Apollo remains steadfast in its belief in the importance of preventive healthcare. Our mission is to empower individuals to safeguard their well-being, preventing the onset of NonCommunicable Diseases (NCDs). In a country where 5.8 million lives are claimed annually by NCDs, and 1 in 4 Indians faces the risk of such an outcome before the age of 70, Apollo ProHealth emerges as a beacon of comprehensive personalized prevention. Combining medical expertise with Artificial Intelligence, this program, curated by skilled physicians, evaluates overall health, predicts risks, and guides individuals on a personalized path to wellness. It equips you with the tools and knowledge to make proactive choices for your well-being.

Our vision is resolute – to integrate preventive healthcare into the lives of every Indian. More than a business objective, it's a commitment to our nation's health. Together, let's strive to nurture countless healthy and happy families, shielding them from the growing threat of noncommunicable diseases.”

Result PDF

Healthcare Facilities company Apollo Hospitals Enterprise announced Q2FY24 & H1FY24 results:

  • Consolidated Q2FY24:
    • Revenue at Rs 48,469 million vs Rs 42,511 million in Q2FY23; growth of 14% YoY
    • EBITDA at Rs 6,276 million vs Rs 5,654 million in Q2FY23. This is after Apollo 247 cost of Rs 1,973 million in the quarter (including Rs 350 million non-cash ESOP charge) vs Rs 1,744 million (including Rs 220 million non-cash ESOP charge) in Q2FY23.
    • Reported PAT at Rs 2,329 million vs Rs 2,040 million in Q2FY23
    • Diluted EPS of Rs 16.20 per share in Q2FY24 (not annualized)
  • Consolidated H1FY24:
    • Revenue at Rs 92,647 million vs Rs 80,467 million in H1FY23; growth of 15% YoY
    • EBITDA at Rs 11,365 million vs Rs 10,561 million in H1FY23. This is after Apollo 247 cost of Rs 4,012 million for H1 (including Rs 643 million non-cash ESOP charge) vs Rs 3,156 million in H1FY23.
    • PAT stood at Rs 3,995 million vs Rs 3,745 million in H1FY23 (Before Deferred tax reversal)
    • Reported PAT stood at Rs 3,995 million vs Rs 5,211 million in H1FY23
    • Diluted EPS of Rs 27.78 per share in H1FY24

Dr. Prathap C Reddy, Chairman, Apollo Hospitals Group, said, "For more than forty years, Apollo has spearheaded a healthcare revolution in India, leading the charge in delivering quality healthcare services throughout the nation. Our unwavering commitment drives us to extend the reach of our services far and wide, bolstered by investments in cutting-edge technologies and the ongoing enhancement of our existing facilities. Our relentless pursuit is to consistently elevate our services, ensuring superior care to our patients who deserve the best quality care and for the trust they placed in us for 40 years. We promise that we shall continue to do our best for them, always.

We are happy to have announced our new hospitals at Pune and Kolkata, and we are forging ahead with our plans to add 2,300 high-quality beds in key geographies over the next three years."

Result PDF

Healthcare Facilities company Apollo Hospitals Enterprise announced Q4FY23 & FY23 results:

  • Q4FY23:
    • Revenues grew 21% to Rs 43,022 million vs Rs 35,464 million in Q4FY22
    • EBITDA excluding 24/7 Operating Cost and ESOP charge stood at Rs 706 million; 29% YoY growth
    • Apollo 24/7 cost of Rs 2,174 million in the quarter (including Rs 281 million non-cash ESOP charge) vs Rs 841 million in Q4FY22
    • EBITDA post 24/7 Operating Cost and ESOP charge at Rs 4,882 million vs Rs 4,632 million in Q4FY22; 5% YoY growth
    • PAT grew 60% to Rs 1,445 million vs Rs 901 million in Q4FY23
    • Diluted EPS of Rs 10.05 per share in Q4FY23 (not annualised)
  • FY23:
    • Revenues grew 13% to Rs 166,125 million vs Rs 146,626 million in FY22
    • EBITDA excluding 24/7 Operating Cost and ESOP charge stood at Rs 27,851 crore ;16% YoY growth
    • Apollo 24/7 cost of Rs 7,355 million for the full year (including Rs 781 million non-cash ESOP charge) vs Rs 2,236 million in FY22
    • EBITDA post 24/7 Operating Cost and ESOP charge at Rs 20,496 million vs Rs 21,851 million in FY22
    • PAT stood at Rs 8,191 million vs of Rs 10,556 million in FY22
    • Diluted EPS of Rs 56.97 per share in FY23

Dr. Prathap C Reddy, Chairman, Apollo Hospitals Group said, “The first full post-pandemic year has seen Apollo make some remarkable strides in its journey of healing. Our unwavering commitment to deliver world-class healthcare has enabled us to scale new heights with our performance - both in terms of financial metrics and in the expansion of our healthcare service offerings. We have seen a substantial increase in patient engagement both in our hospitals and clinics, as well as on our digital health platform Apollo 24/7.

We have continued to broaden our services, ensuring that we focus not just on cure, but on preventive healthcare as well. At a time when the world is realizing the importance of prevention more than ever before, it is a matter of pride that Apollo has been at the forefront of this shift, recognizing that the best way to fight disease is to prevent it in the first place. One of our areas of focus is Artificial Intelligence (Al), which we believe holds the power to revolutionize preventive healthcare, by helping identify patterns, predict health risks, and enable early interventions. This year, we have invested thoughtfully in Al technologies, and the results have been heartening. They have allowed us to provide a personalized healthcare approach for every individual, taking into account their unique genetic disposition, lifestyle, and medical history."

 

Result PDF

Healthcare Facilities firm Apollo Hospitals Enterprise announced Q1FY23 Result :

  • Q1FY23 Revenues at Rs. 3,796 crs Growth of 7% over Q4 FY22
  • EBITDA (Pre Apollo 247 ramp up costs) at Rs 626 crs Growth of 14% over Q4FY22
  • Apollo 247 operating costs of Rs 135 crs in Q1 FY23 vs. Rs 84 crs in Q4FY22
  • GMV of Apollo 247 at Rs 215 crs vs. Rs 177 crs in Q4FY22
  • On track to deliver 1500 crs. of GMV in FY22-23
  • EBITDA (Post Apollo 247 costs) at Rs.491 crs growth of 6% over Q4FY22
  • Reported PAT at Rs. 317 crs, after deferred tax reversal of Rs 147 crs
  • Adjusted PAT at Rs 171 crs, compared to Rs 178 crs in Q4FY22
  • Diluted EPS of Rs.22.05 per share in Q1FY23 (not annualised)

Dr Prathap C. Reddy, Chairman, Apollo Hospital Group said, "The first quarter of the new financial year has seen a definitive increase in the demand for non-CO VID health services and augurs well for growth this financial year. We have been able to serve a larger number of patients with non-communicable diseases (NCDs) and restore them to health. At the same time, our focus on preventive healthcare has continued to help patients manage chronic conditions and nip them in the bud. 

With the overall economy emerging from the shadow of the pandemic, we have seen people returning to office and life coming back to normaL However, we continue to maintain precautions against COVID and remain vigilant and prepared against new infections such as monkeypox, which has been declared as a global health emergency by the World Health Organisat/on.

We are glad to report increased progress in our digital initiatives. Our cardiovascular risk assessment tool is now integrated with Singapore-based ConnectedLife 's digital wellness solutions and is an acknowledgement of our innovative work in preventive healthcare. We are the first system in Asia Pacific to be awarded three Stage 6 certifications for H/MSS (Healthcare In formation and Management Systems Society) digital maturity models and the second system in the world to be awarded a Stage 6 DIAM certification. The DIAM validation commended us for our use of biomarkers, molecular imaging, and mapping software. Our patient portal was commended as "one of the finest examples of patient communication" with multiple functionalities, including appointment setting, health monitoring and device integration capability.

It is recognition such as this that continues to motivate us to grow our digital health capabilities and leverage the full potential of digital technology for the best patient outcomes. Our aim remains to empower our patients and encourage them to proactively manage their own health, a factor that is increasingly considered as vital to improve the quality of healthcare. Our digital prowess is also empowering our doctors with digital tools to help patients realize their health goals.

We are a/so preparing to utilize the power of 5G in healthcare. 56 technology can provide a solid security foundation for sharing vital patient data remotely. We partnered with Airtel and CISCO on a use case of a 56 connected ambulance to showcase how 56 technology can virtually transport doctors into the Ambulance to provide critical care even as the patient is enroute to the hospital in an emergency. We are excited about our acquisition of the hospital asset in 6urgaon, and we look forward to taking our unique brand of world class clinical outcomes to the fast-growing and discerning city. All our centres of excellence are now performing effectively and efficiently with digitization integrated into the healthcare delivery ecosystem. Out digital healthcare services platform Apollo 24/7 is also progressing faster than planned, with our physical pharmacy network poised to touch 5000 stores. Apollo Hospitals is now well poised to grow across all verticals this year!."

 

Result PDF

Apollo Hospitals Enterprise declares Q4FY22 result:

  • Q4 FY22 Consolidated Revenues of Rs 35,464 mio (growth of 24% yoy).
  • Q4 FY22 Consolidated EBITDA (Post Ind AS 116) of Rs 4,632 mio.
  • New Hospitals (excl Proton) reported an EBITDA of Rs 826 mio in Q4 FY22 as compared to an EBITDA of Rs 677 mio in Q4 FY21.
  • Proton reported EBITDA (Post Ind AS 116) of Rs 139 mio in Q4 FY22 as compared to EBITDA of Rs 25 mio in Q4 FY21.
  • AHLL reported EBITDA (Post Ind AS 116) of Rs 371 mio in Q4 FY22 as compared to EBITDA Rs 305 mio in Q4FY21.
  • Consolidated PAT of Rs 901 mio in Q4 FY22. PAT before adjusting for tax (business combination U/s Ind AS 103) is Rs 1,783 mio.
  • Ind-AS 116 on operating lease impacted reported PBT in Q4FY22 to the extent of Rs 119 mio.
  • Q4FY22 occupancy across the group was at 4,604 beds (58% occupancy) as compared to 4,631 beds (63% occupancy) in Q4FY21. The Q4FY22 occupancy in mature hospitals was at 3,284 beds (60% occupancy). New hospitals had an occupancy of 1,320 beds (55%) occupancy) in Q4FY22.
  • Inpatient Volumes across the group increased by 7% from 108,169 to 115,902.
  • ARPOB (excluding vaccination) was at Rs 48,510 Vs Rs 43,239 registering a growth of 12% in Q4 FY22 as compared to the same period previous year.

 

 

Result PDF

Apollo Hospitals Enterprise declares Q3FY22 result:

  • Q3 FY22 Consolidated Revenues of Rs 36,389 mio (growth of 32% yoy).
  • Q3 FY22 Consolidated EBITDA (Post Ind AS 116) of Rs 5,870 mio.
  • New Hospitals (excl Proton) reported an EBITDA of Rs 1,189 mio in Q3 FY22 as compared to an EBITDA of Rs 645 mio in Q3 FY21.
  • Proton reported EBITDA (Post Ind AS 116) of Rs 156 mio in Q3 FY22 as compared to EBITDA of Rs 17 mio in Q3 FY21.
  • AHLL reported EBITDA (Post Ind AS 116) of Rs 495 mio in Q3 FY22 as compared to EBITDA  Rs 278 mio in Q3FY21.
  • Consolidated PAT of Rs 2,284 mio in Q3 FY22.
  • Ind-AS 116 on operating lease impacted reported PBT in Q3FY22 to the extent of Rs 107 mio
  • Q3FY22 occupancy across the group was at 5,107 beds (65% occupancy) as compared to 4,658 beds (63% occupancy) in Q3FY21. The Q3FY22 occupancy in mature hospitals was at 3,575 beds (66% occupancy). New hospitals had an occupancy of 1,532 beds (63%) occupancy) in Q3FY22.
  • Inpatient Volumes across the group increased by 28% from 99,197 to 127,441.
  • ARPOB (excluding vaccination) was at Rs 46,062 Vs Rs 40,092 registering a growth of 15% in Q3 FY22 as compared to the same period previous year.
  • Q3FY22 Consolidated Revenues at Rs 36,389 mio
  • Q3FY22 Consolidated EBITDA at Rs 5,870 mio
  • Q3FY22 Consolidated PAT at Rs 2,284 mio

 

Result PDF

Highlights:

  • Apollo Hospitals set to acquire a majority stake in 180-bed Excelcare Hospitals in Guwahati.
  • Acquisition strengthens Apollo's leadership position in the city, with a combined capacity now of 400 beds (including the existing hospital)
  • Indicates Group's strong focus on the North East, and intent to provide high quality healthcare across the country
  • Q2 FY22 Consolidated Revenues of Rs 37,171 mio (growth of 35% yoy).
  • Q2 FY22 Consolidated EBITDA (Post Ind AS 116) of Rs 6,150 mio.
  • New Hospitals (excl Proton) reported an EBITDA of Rs 1,277 mio in Q2 FY22 as compared to an EBITDA of Rs 387 mio in Q2 FY21.
  • Proton reported EBITDA (Post Ind AS 116) of Rs 139 mio in Q2 FY22 as compared to EBITDA loss of Rs (19) mio in Q2 FY21.
  • AHLL reported EBITDA (Post Ind AS 116) of Rs 621 mio in Q2 FY22 as compared to EBITDA Rs 213 mio in Q2FY21.
  • Consolidated PAT of Rs 2,478 mio in Q2 FY22,
  • Ind-AS 116 on operating lease impacted reported PBT in Q2FY22 to the extent of Rs 116 mio

 

Result PDF

Trending News

Midhani has secured an order of Rs. 121.75 crore

Midhani has secured an order of Rs. 121.75 crore

Published on 19-Dec-2025 09:02

Aeroflex Industries Board has approved a ₹97.56 crore expansion plan

Aeroflex Industries Board has approved a ₹97.56 crore expansion plan

Published on 19-Dec-2025 09:01

As per media sources, HDFC Bank has raised a $1 billion three-year overseas loan from its GIFT City branch

As per media sources, HDFC Bank has raised a $1 billion three-year overseas loan from its GIFT City branch

Published on 19-Dec-2025 09:00

TCS, on its Investor Day 2025, articulated a clear shift towards an AI-first enterprise

TCS, on its Investor Day 2025, articulated a clear shift towards an AI-first enterprise

Published on 18-Dec-2025 09:07

Syrma SGS Technology has completed the first tranche of its acquisition of defence and aerospace electronics firm Elcome Integrated Systems

Syrma SGS Technology has completed the first tranche of its acquisition of defence and aerospace electronics firm Elcome Integrated Systems

Published on 18-Dec-2025 09:06

POWERGRID has commissioned the Western Region Expansion Scheme-XXV

POWERGRID has commissioned the Western Region Expansion Scheme-XXV

Published on 18-Dec-2025 09:05

Disclaimer – I ICICI Securities Ltd. ( I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is acting as a distributor to solicit bond related products. All disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein mentioned are solely for informational and educational purpose.
Download App

Download Our App

Play Store App Store
market app
✕
Application status